<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195688</url>
  </required_header>
  <id_info>
    <org_study_id>1279.1</org_study_id>
    <secondary_id>2010-021187-15</secondary_id>
    <nct_id>NCT01195688</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1-700 mg) of BI 638683 Powder in Bottle (PiB) in Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of the current study is to investigate the safety and tolerability of
      BI 638683 in healthy male volunteers following oral administration of single rising doses
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of BI 638683 will be assessed in a descriptive way.</measure>
    <time_frame>up to 14 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of BI 638683 will be assessed in a descriptive way.</measure>
    <time_frame>up to 14 days post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess pharmacodynamics of BI 638683.</measure>
    <time_frame>up to 5 days post study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess pharmacokinetics of BI 638683.</measure>
    <time_frame>up to 5 days post study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 638683</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 single dose per subject as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 single dose per subject as oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 638683 or placebo</intervention_name>
    <description>oral doses given to 6 subjects per dose group</description>
    <arm_group_label>BI 638683</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo solution</intervention_name>
    <description>oral doses given to 2 subjects per dose group</description>
    <arm_group_label>Placebo solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        healthy male subjects
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1279.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <last_update_submitted>June 1, 2011</last_update_submitted>
  <last_update_submitted_qc>June 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

